ZHONGHUA YANGSHENG BAOJIAN ›› 2025, Vol. 43 ›› Issue (11): 173-176.

Previous Articles     Next Articles

Study on the Relationship between Immune Tlymphocyte Subsets and the Efficacy and Prognosis of Chemotherapy Combined Targeted Therapy in Patients with Advanced Colorectal Cancer

CAO Ting1, XIAO Yin2, ZHANG Cheng2, ZHENG Guang2, WANG Jue2, HUANG Shi-ying3, HE Xin2,*   

  1. 1. Department of Basic Pathology, School of Pathology, Qiqihar Medical University, Qiqihar Heilongjiang, 161000, China;
    2. Department of Oncology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar Heilongjiang, 161000, China;
    3. Department of Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar Heilongjiang, 161000, China
  • Online:2025-06-01 Published:2025-09-23

PDF (PC)

0

Abstract: Objective To explore the relationship between immune T lymphocyte subsets and the efficacy and prognosis of patients with advanced colorectal (CRC) cancer treated with chemotherapy combined with targeted therapy. Methods A total of 85 patients with advanced CRC were selected from January 2024 to October 2024. All patients received chemotherapy combined with targeted therapy. After 4 cycles, the efficacy of the two groups was compared. According to the efficacy of the patients, they were divided into a control group (55 cases, complete response + partial response + stable disease) and an ineffective group (30 cases, disease progression). The immune function and tumor indexes were compared between the two groups. Results Before treatment, there was no significant difference in the levels of CD3+T cells, CD4+T cells, CD8+T cells and CD4+/CD8+ between the two groups (P>0.05). After treatment, the levels of CD3+T cells, CD4+T cells and CD4+/CD8+ in the control group were higher than ineffective group, and the levels of CD8+T cells in the control group were lower than those in the ineffective group, with statistical significance (P< 0.05). Before treatment, there was no significant difference in tumor abnormal protein (TAP), Carbohydrate antigen 125 (CA125) and Carbohydrate antigen 199 (CA199) levels between the two groups (P>0.05). After treatment, TAP, CA125 and CA199 levels in the control group were lower than ineffective group, and the difference was statistically significant (P<0.05). After treatment, the levels of CD3+ T cells, CD4+ T cells, CD4+/CD8+ were negatively correlated with the therapeutic effect (P<0.05), and the levels of CD8+ T cells were positively correlated with the therapeutic effect (P<0.05). Conclusion Immune T lymphocyte subsets are potentially related to the efficacy of chemotherapy combined with targeted therapy in patients with advanced colorectal cancer, which is of great significance for the prognosis of patients.

Key words: advanced colorectal cancer, immune T lymphocyte subsets, immune function, tumor index

CLC Number: